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STEM CELL LEGISLATION: AN INTERNATIONAL
AND COMPARATIVE DISCUSSION
Meredith Mariani*
Stem cells, because of their scientific and biomedical potential, cap-
tured the attention of the international community and thrust scientific inno-
vation and discovery into the forefront of international legal, political, reli-
gious, and ethical discourse. The potential scientific and medical promise of
embryonic and adult stem cells spread rapidly throughout the international
community and sparked heated debate regarding the future uses and applica-
tions of these versatile and unique cells. Since research involving stem cells
also addresses equally difficult areas such as human cloning, human embry-
onic research, and the legal status of the early embryo, the discussions and
resulting global legislative efforts have been highly charged and wrought
with theoretical, as well as practical, challenges. Scientific research and
innovation have never been easily legislated or regulated fields. The inter-
play between the need for scientific freedom to facilitate the development
and advancement of cutting edge research in controversial areas such as stem
cell research and human cloning and the legislative regulation of such activi-
ties has always been a delicate one. This needed balance has not always
been achieved. The achievement of any tenuous balance between regulation
and scientific research is affected by the nature of science itself. Every sci-
entific discovery has its complications, as well as far-reaching corollary ef-
fects into other aspects of human society. Stem cell research is more prob-
lematic than other biomedical issues, such as organ transplantation or gene
therapy, because of its ties to cloning. Cloning, another rapidly developing
field of biomedical research has become the subject of legislative regulation
along with stem cell research.
There are two types of cloning, therapeutic and reproductive. These
two types of cloning are distinguished by the purposes to be fulfilled by the
cloned embryos. Therapeutic cloning is tied to the production of stem cells
and thus has a more direct connection to stem cell research than reproductive
cloning because it provides a viable and rejection-free source of embryonic
* Candidate for Juris Doctor, Notre Dame Law School, 2003. I would like to thank my family for their sup-
port and advice. I would also like to thank Kellie McVaugh for her sharp eye, endless patience, and the sacri-
fice of some summer afternoons.
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stem cells.1 Thus, any law or regulation enacted or amended to deal with
stem cell research would have to address cloning in some way. This has
proved to be a complex and restrictive development and thus makes the cur-
rent global legislative process addressing this research even more challeng-
ing and complicated.
Both the United Kingdom and the United States have been attempt-
ing to address stem cell research by means of legislation and are in the proc-
ess of creating and developing different legislative schemes responsive to the
interests and perceptions of their respective governments and populations.
The United States and the United Kingdom provide an interesting vantage
point for comparison regarding stem cell legislation. Both countries have a
common law background and share some similar legal institutions and per-
spectives. However, their respective approaches and legislative schemes
regarding stem cells are quite different and illustrate how two somewhat
similar countries in terms of general legal background and perspective can
vary widely with respect to this aspect of biomedical legislation. This com-
parative discussion will illustrate the difficulties resulting from an attempt
for international legislative harmonization addressing stem cell research and
is further demonstrated by examining the current legislative situation on the
regional and international level. Given the wide variety of viewpoints on
this topic, regional and international organizations face a difficult and slow
road ahead, especially when member states run into similar roadblocks with
respect to the scientific, legislative, and ethical consensus required to create
useful and applicable legislation.
This Note will focus on the legislative responses to the area of stem
cell research in the United Kingdom and the United States. Section I will
describe the characteristics and origins of stem cells and the challenges in-
herent in utilizing this technology. Section II will discuss the legislative
situation already in place in the UK and how Parliament is attempting to
adapt current legislation to accommodate stem cell research and cloning.
Section III will address the US position on stem cell research and how that
position is influencing its attempts to create a statutory scheme regulating
such research. Section IV examines the legislative situation at the regional
and international level, focusing on the United Nations, the Council of
Europe, and the European Union, and the directions these organizations are
attempting to pursue, as well as the international impact of such approaches.
Section V will examine where all of these legislative efforts leave both the
United Kingdom and the United States and in what direction these two coun-
tries seem to be moving, domestically and internationally.
1. Tissues resulting from stem cell lines acquired by cell nuclear replacement would be genetically
compatible with the individual being treated and there would most likely be no rejection. Department of
Health, Donaldson Report Stem Cell Research: Medical Progress with Responsibility, Box 9 at 24, at
http://www.doh.gov.uk/cegc/stemcellreport.htm, (August 16, 2000) (on file with author).
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SECTION I: THE SCIENCE BEHIND STEM CELLS
What are stem cells? What is it about the nature of these cells that
has made their entry into the international public consciousness such a tu-
multuous one? Stem cells are unspecialized cells at an early stage of devel-
opment.2 Stem cells can divide and differentiate into numerous cell types
that comprise the tissues and organs of the body.3 Stem cells are also able to
undergo self-renewal, a process "by which an unspecialized stem cell divides
to produce two further unspecialized stem cells."4 In the human body, most
specialized cells do not actually divide but are replaced or replenished from
populations of stem cells present in most of the tissues of the body.' Stem
cells fulfill a central role in human growth and development and also provide
a continuous source of new cells for the regeneration of diseased or damaged
tissue.' Stem cells, both embryonic and adult7, can theoretically replicate
themselves indefinitely in culture and are able to generate more specialized
cells as they proliferate.8 The scientific and medical potential of stem cells
comes from their ability to be stabilized and grown in the laboratory and
influenced, when needed, to differentiate into more specialized, mature cells
and tissues that could be utilized for treatment. 9
Stem cells are present at all stages of human development, but their
trademark versatility and abundance decrease with age and are their highest
in the embryonic stage. o Embryonic stem cells are perceived to be able to
produce any of the 200 different types of the specialized cells that make up
the human body, such as blood, neural, and liver cells."t This specialization
occurs through a process called differentiation, which involves less special-
ized cells developing into more specialized cells. 12 In order to appropriately
and correctly understand stem cells, a basic grasp of human embryonic de-
velopment is necessary. A significant amount of the inaccuracy and confu-
2. Department of Health, Donaldson Report Stem Cell Research: Medical Progress with Responsibility,
Section 2.6 at 17, at http://www.doh.gov.uk/cegc/stemcellreport.htm (Aug. 16, 2000) (on file with author).
3. Id.
4. Id.
5. House of Lords, Select Committee on Stem Cell Research Report, Chapter 2 § 2.2, at
http://www.publications.parliament.uk/pa/Id200102/Idselect/Idstem/83/830 l.htm (Feb. 13, 2002) (on file with
author).
6. Id.
7. With regard to stem cells, 'adult' and 'embryonic' refer to the source of the cells. Adult stem cells are
obtained from adults, whereas embryonic stem cells are obtained from early embryos.
8. House of Lords, Select Committee on Stem Cell Research Report, Chapter 3 § 3.3, at
http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem!83/8301.htm (Feb. 13, 2002) (on file with
author).
9. Department of Health, Donaldson Report Stem Cell Research: Medical Progress with Responsibility,
Section 2.7 at 18, at http://www.doh.gov.uk/cegc/stemcellreport.htm (Aug. 16, 2000) (on file with author).
10. The Royal Society, Stem Cell Research and Therapeutic Cloning, at
http://www.royalsoc.ac.uk/policy/stemcells.htm, (November 2000) (on file with author).
11. House of Lords, Select Committee on Stem Cell Research Report, Chapter 2, at
http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem/83/830l.htm (Feb. 13, 2002) (on file with
author).
12. Id. atBox2.
2002]
Journal of Legislation
sion that infiltrates the stem cell debate comes from misconceptions regard-
ing the stages of human development.
After fertilization, the resulting zygote 3 then undergoes numerous
cell divisions in the next thirty-six hours. 14  For the first eight cell divisions
after fertilization, all of the cells are considered totipotent, which means that
each cell has the capacity to develop into all cell types required for human
development, including the non-embryonic tissues such as the umbilical cord
and the placenta. 5  Totipotent stem cells can be defined in two different
ways. They are either cells that have the potential to develop into an adult
organism if placed in the right environment or as cells that give rise to every
cell line in the developing fetus.' 6 Totipotent cells only exist for a short pe-
riod during early embryonic development. 7 After five days of cell division,
these totipotent cells begin to specialize, forming a hollow sphere of cells
called a blastocyst.' 8 The blastocyst has an outer layer of cells and within
the hollow sphere, there is a cluster of cells called the inner cell mass.' 9 It is
from the inner cell mass that embryonic stem cells can be obtained and from
which the embryo develops.20 The cells from the inner cell mass cannot de-
velop into an organism because the outer layer of cells, as well as some of
the cells from the inner cell mass, have already differentiated and cannot
form the supporting tissues for fetal development. 2' Thus, the inner cell
mass can only proliferate and specialize into all the cell types found in the
human body. As development proceeds beyond the blastocyst stage, the
stem cells comprising the inner cell mass continue to differentiate and spe-
cialize into cells that are committed to expressing a particular function.22
The inner mass cells are called pluripotent; these cells can give rise to almost
all the cells in the human body except for those needed for fetal develop-
ment. 23 Thus, their potential is not total, like the totipotent cells immediately
following fertilization. 24 As differentiation continues, the amount of pluripo-
13. A zygote is the end result of the process of fertilization stemming from the fertilization of the female
egg (oocyte) by the male sperm.
14. House of Lords, Select Committee on Stem Cell Research Report, Chapter 4 Section 4.2(b), at
http://www.publications.parliament.uk/pa/ld200lO2/ldselect/ldstem/83/8301.htm (Feb. 13, 2002) (on file with
author).
15. Id. at Chapter 2.
16. Nuffield Council on Bioethics, Stem Cell Therapy: the ethical issues, at
http://www.nuffieldbioethics.org/stemeells/index.asp (Dec. 10, 2001) (on file with author).
17. Id.
18. House of Lords, Select Committee on Stem Cell Research Report, Chapter 2 § 2.3, at
http://www.publications.parliament.uk/pa/ld200lO2/ldselect/ldstem/83/8301.htm (Feb. 13, 2002) (on file with
author).
19. Id. at Chapter 4 § 4.2(c).
20. Id.
21. Nuffield Council on Bioethics, Stem Cell Therapy: the ethical issues, at
http://www.nuffieldbioethics.org/stemcells/index.asp (Dec. 10, 2001) (on file with author).
22. House of Lords, Select Committee on Stem Cell Research Report, Chapter 2, at
http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem/83/8301.htm (Feb. 13, 2002) (on file with
author).
23. Id.
24. Id.
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tent stem cells in the embryo begins to decrease, resulting ultimately in a
smaller amount of stem cells in the human body.25 Yet, most tissues in both
the fetus and adult body do contain unspecialized stem cells that have the
,potential to differentiate into a specific cell type but are used to regenerate or
repair damaged tissues.26
These more specialized cells are called multipotent and have a more
restricted potential than the embryonic stem cells found in the inner cell
mass prior to differentiation.27 These multipotent cells give rise to most of
the present cell types in the human body.28 Tissues outside of the embryo,
such as the placenta and the umbilical cord, also provide a source of multi-
potent stem cells and consist of the same genetic make-up as the embryo.29
Hematopoetic stem cells, those found in the bone marrow of every child and
adult, can also be found in minute numbers circulating within the blood-
stream.30 They can give rise to different cell types present in the blood but
cannot develop into other differentiated cells, such as neural cells.31 Pluripo-
tent stem cells represent a very specific class of stem cells and can only be
obtained from the blastocyst.32 Other stem cells, as illustrated above, can be
obtained from the embryo at later stages of development, but these stem cells
are not pluripotent and resemble adult stem cells more than embryonic stem
cells.33
Embryonic pluripotent stem cells can be obtained from three sources.
First, as stated, embryonic stem cells can be obtained directly from the inner
cell mass of early human embryos at the blastocyst stage created by in vitro
fertilization.34 Second, fetal 'tissue from terminated pregnancies can also
provide a source of stem cells, which may be pluripotent or multipotent de-
pending on the stage of embryonic development.3 5  Third, cell nuclear re-
placement is a possible source of stem cells.3 6 This procedure, otherwise
25. House of Lords, Select Committee on Stem Cell Research Report, Chapter 2 § 2.4, at
http://www.publications.parliament.uk/pa/ld200lO2/ldselect/ldstem/83/8301.htm (Feb. 13, 2002) (on file with
author).
26. Id
27. Id. at Chapter 2, Box 2.
28. Id.
29. Id. at Chapter 2 § 2.4.
30. These blood stem cells are responsible for continually replenishing our blood cells - white blood cells,
red blood cells and platelets. House of Lords, Select Committee on Stem Cell Research Report, Chapter 2 at
Box 2, at http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem/83/8301.htm (Feb. 13, 2002).
(on file with author)
31. Id.
32. House of Lords, Select Committee on Stem Cell Research Report, Chapter 2 § 2.5, at
http://www.publications.parliament.uk/pa/ld200lO2/ldselect/ldstem/83/8301.htm (Feb. 13, 2002). (on file with
author)
33. Id.
34. Stem Cell Research and Regulations under the Human Fertilization and Embryology Act 1990 House
of Commons Research Paper, at http://www.parliament.uk/commons/lib/research/rp2000/rpOO-093.pdf (Dec.
13, 2000) (on file with author).
35. House of Lords, Select Committee on Stem Cell Research Report, Chapter 2 §§ 2.4 & 2.5, at
http://www.publications.parliament.uk/pa/ld200lO2/ldselect/ldstem/83/8301.htm (Feb. 13, 2002) (on file with
author).
36. Id. at Chapter 2, Box 2.
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known as therapeutic cloning, involves removing the nucleus of an egg cell
and replacing it with the nucleus of a somatic cell. This procedure will be
discussed further below.
Adult stem cells are also considered a potential source of stem cells
but are not thought to possess the same level of versatility as the embryonic
pluripotent stem cells; the majority of adult stem cells are thought only to
have the potential to develop into the type of tissue from which taken from.37
Adult stem cells are multipotent cells present in many tissues in the human
body and are required for regeneration and repair. The therapeutic potential
of adult stem cells has been demonstrated by the successful use of hemato-
poetic stem cells for the treatment of leukemias and other blood disorders.38
Recent studies have illustrated that adult stem cells may contain greater
therapeutic potential than previously perceived. 39 This potential increase in
therapeutic applicability has allowed for further consideration of adult stem
cells as a possible viable alternative source of stem cells. However, adult
stem cells are difficult to isolate and maintain due to their limited availabil-
ity in adult tissues.40 Another roadblock to the overall therapeutic viability
of adult stem cells is the inability of such cells, once isolated, to differentiate
into other cell types.4' Adult stem cells serve the purpose of regeneration
and repair only in specific tissues and thus do not possess the wide elasticity
apparent in embryonic stem cells. It has been suggested that re-
differentiation of adult stem cells could possibly widen their use as a thera-
peutic alternative to embryonic stem cells.42 Such understanding, at this
point, regarding re-differentiation of adult stem cells, as well as the process
of differentiation overall, is still very limited.43 Some have suggested that
developments regarding adult stem cells make research on embryonic stem
cells unnecessary, thus removing the need for research involving embryos.44
The majority of scientists do not share this view and do not perceive adult
stem cells as an alternative to embryonic stem cells but rather as complimen-
tary pathways to therapy.45 The general view has emphasized the need for
continuing research on all fronts of stem cell research, both adult and em-
bryonic stem cells.
37. Department of Health, Donaldson Report Stem Cell Research: Medical Progress with Responsibility,
Section 2.13, at http://www.doh.gov.uk/cegc/stemcellreport.htm (Aug. 16, 2000) (on file with author).
38. House of Lords, Select Committee on Stem Cell Research Report, § 3.8, at
http://www.publications.parliament.uk/pa/ld200102/idselect/ldstem/83/8301.htm (Feb. 13, 2002). (on file with
author)
39. Id. at § 3.9.
40. Id. at § 3.11.
41. Id. at §§ 3.12 & 3.14.
42. House of Lords, Select Committee on Stem Cell Research Report, § 2 Box 3, at
http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem/83/8302.htm (Feb. 13, 2002) (on file with
author).
43. House of Lords, Select Committee on Stem Cell Research Report, § 3.12, at
http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem/83/8301.htm (Feb. 13, 2002) (on file with
author).
44. Id. at § 3.16.
45. Id.
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Both embryonic and adult stem cells hold promise that is only begin-
ning to be understood. One aspect of stem cell research that has garnered a
large amount of attention is the interplay between the availability of embry-
onic stem cells and cloning. Cloning has been mentioned as providing a
possible source of embryonic stem cells that would be available for thera-
peutic and research demands that in vitro fertilization or other sources of
stem cells might not be able to fulfill. Yet cloning is very problematic and
has generated a lot of apprehension and debate in respect to its possible con-
nections with stem cell research. Thus, it is important to clarify what clon-
ing means, how cloning fits in with stem cell research, and why this connec-
tion is important for developing legislation addressing stem cell research.
There are two forms of cloning and both have been associated with
and discussed in light of stem cell research: therapeutic cloning and repro-
ductive cloning. Cell nuclear replacement is the process by which the nu-
cleus of an adult specialized cell is inserted into a mature but unfertilized
egg that has had its original nucleus deactivated and removed.4 6 Following
this procedure, if the recipient egg is induced, by means of chemical or hor-
monal stimulation, to divide, an embryo can be produced.4 ' The term thera-
peutic cloning refers more to the use of the subsequent product of cell nu-
clear replacement rather than an actual procedure. 48 Thus, therapeutic clon-
ing is the use of the resulting embryo created by cell nuclear replacement for
research and therapeutic purposes, by generating embryonic stem cells for
direct application in treatment.49 In this situation, the embryo itself is only
permitted to develop to the blastocyst stage and is not allowed to develop
into an embryo or be implanted in a woman's uterus.5" On the other hand,
reproductive cloning refers to the actual implantation of the blastocyst result-
ing from cell nuclear replacement into a woman's uterus with the intent of
producing a baby.5' So the crucial distinction between reproductive and
therapeutic cloning comes from the steps taken after cell nuclear replacement
that reflect the purpose of performing the procedure. The main use of thera-
peutic cloning in stem cell research is to provide a source of stem cells tai-
lored to a particular patient, thus mitigating the problem of rejection and the
need for immunosuppression drugs.52
Embryonic stem cells hold promise as both a research tool and a
potential treatment for a number of life-threatening diseases. Yet there are
46. House of Lords, Select Committee on Stem Cell Research Report, § 5.6, at
http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem/83/8301.htm (Feb. 13, 2002) (on file with
author).
47. H.R REP. No. 107-170, at http://www.house.gov/judiciary/legreports.htm (July 27, 2001).
48. House of Lords, Select Committee on Stem Cell Research Report, § 5.8, at
http://www.publications.parliament.uk/pa/ld200102/Idselect/ldstem/83/830 l.htm (Feb. 13, 2002).
49. Id. at § 5.8
50. Id.
51. Id. at § 5.5.
52. Department of Health, Donaldson Report Stem Cell Research: Medical Progress with Responsibility §
2.28, at http://www.doh.gov.uk/cegc/stemcellreport.htm (Aug. 16, 2000) (on file with author).
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many concerns associated with these cells, including whether they can be
successfully cultivated in the laboratory, how these cells should be utilized,
and where they should be obtained from, if at all. Governments are strug-
gling to deal with both the promise of stem cells as well as the ethical and
legal difficulties they present. Two countries attempting to work with these
cells are the United Kingdom and the United States. They represent two
divergent legislative approaches to stem cell research and they will deter-
mine if the potential of these highly versatile and therapeutically promising
cells will be realized. But in order to address stem cells, both the United
Kingdom and the United States have to address their potential sources. The
concerns surrounding human cloning have infiltrated this debate and now
play an important role as to the actual direction any legislative response will
take.
SECTION II: THE UNITED KINGDOM
The United Kingdom has taken a very progressive stance towards
stem cell research and human cloning, as compared to the rest of Europe and
the United States. The focus of the stem cell research debate in the United
Kingdom hinges on the Human Fertilization and Embryology Act 1990 (the
Act), which was enacted to "regulate the practice of in vitro fertilisation and
the creation, use, storage and disposal of embryos formed by this means."53
However, the Act does not regulate research on stem cells once they are re-
moved from embryos or research on stem cells acquired from non-embryonic
sources such as adult stem cells or an aborted fetus.54
The specific scope of the Act, as stated in the Preamble of the Act, is
to make provisions in connection with human embryos and any subsequent
development of such embryos; to prohibit certain practices in connection
with embryos and gametes; to establish the Human Fertilization and Embry-
ology Authority; to make provision(s) about the person(s) who in certain
circumstances are to be treated in law as parents of the child; and to amend
the Surrogacy Agreements Act 1985.15 The Act establishes a regulatory au-
thority, the Human Fertilization and Embryology Authority (HFEA),56
53. House of Lords, Select Committee on Stem Cell Research Report, Chapter 1 § 1.1, at
http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem/83/8301.htm (Feb. 13, 2002) (on file with
author).
54. Department of Health, Donaldson Report Stem Cell Research: Medical Progress with Responsibility,
§ 16, at http://www.doh.gov.uk/cegc/stemcellreport.htm (Aug. 16,2000) (on file with author).
55. An Act to make provision in connection with human embryos and any subsequent development of
such embryos; to prohibit certain practices in connection with embryos and gametes; to establish a Human
Fertilisation and Embryology Authority; to make provision about the persons who in certain circumstances are
to be treated in law as the parents of a child; and to amend the Surrogacy Arrangements Act 1985.
Human Fertilization and Embryology Act 1990 (c.37), at http://www.hmso.gov.uk/acts/actsl990/ Uk-
pga_19900037 en 2.htm#mdiv8 (November 1, 1990) (on file with author).
56. Article 5 of the Act addresses the composition, membership, and other administrative concerns related
to the HFEA.
(1) There shall be a body corporate called the Human Fertilisation and Embryology Au-
thority. (2) The Authority shall consist of- (a) a chairman and deputy chairman, and (b)
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which, under strict conditions, is responsible for monitoring and licensing
clinics that carry out in vitro fertilization, donor insemination, and human
embryo research.57
The purposes of the HFEA, as enumerated in Article 8 of the Act,
specifically place most of the scope of the Act under the jurisdiction of the
HFEA. 5' The HFEA, thus, is responsible for undertaking the review of in-
formation about embryos and subsequent embryonic development, as well as
the review of provisions regarding treatment services and activities governed
under the Act.59 The HFEA is also responsible for publicising "the services
provided to the public by the Authority or provided in pursuance of li-
cences," 60 as well as providing information and advice to those whom the
licenses apply, those who are receiving treatment services, or those provid-
ing gametes and embryos for use under the scope of the Act.61 Article 8(d)
also provides for the broadening of the scope of the Act by permitting the
HFEA to carry out any functions specified in subsequent regulations that are
considered a general function of the HFEA.62 Article 8(d) could permit stem
cell research to be included under the Act because stem cell research could
be considered a "general purpose" of the HFEA due to its close ties, in terms
of sources and possible goals, to in vitro fertilization and human embryo
research, which is what the HFEA does license for.
Under the general supervision of the HFEA, as enumerated under Ar-
ticle 9,63 committees will be created and maintained in order to address one
of the HFEA's main functions-the granting and maintaining of licenses
regarding human embryo research. 4 A substantial portion of the Act ad-
dresses the subject of the licensing committees, including the formation of
such number of other members as the Secretary of State appoints. (3) Schedule 1 to this
Act (which deals with the membership of the Authority, etc.) shall have effect.
1d.
57. Nuffield Council on Bioethics, Stem Cell Therapy: The Ethical Issues, at
http://www.nuffieldbioethics.org/filelibrary/doc/stem cell therapy2.doc (2000) (on file with author).
58. HFEA states:
The Authority shall-(a) keep under review information about embryos and any subse-
quent development of embryos and about the provision of treatment services and activi-
ties governed by this Act, and advise the Secretary of State, if he asks it to do so, about
those matters, (b) publicise the services provided to the public by the Authority or pro-
vided in pursuance of licenses, (c) provide, to such extent as it considers appropriate,
advice and information for persons to whom licenses apply or who are receiving treat-
ment services or providing gametes or embryos for use for the purposes of activities
governed by this Act, or may wish to do so, and (d) perform such other functions as
may be specified in regulations.
Human Fertilization and Embryology Act 1990 (c.37) Article 8, at http://www.hmso.gov.uk/
acts/acts1990/Ukpga_19900037_en_2.htm#mdiv8 (November 1, 1990) (on file with author).
59. Id.
60. Id.
61. Id.
62. Id.
63. "The Authority shall maintain one or more committees to discharge the Authority's functions relating
to the grant, variation, suspension, and revocation of licenses, and a committee discharging those functions is
referred to in this Act as a 'license committee."' Human Fertilization and Embryology Act 1990 (c.37) Article
9(1), at http://www.hmso.gov.uk/acts/acts1990/Ukpga 19900037_en_2.htm#mdiv8 (November 1, 1990)
64. Id.
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the licensing committees themselves as well as the scope, conditions, grant-
ing, and revocation of the licenses. 65 The Act also provides various civil and
criminal sanctions for activities governed by the Act, as stated in Article
41 .66 The sanctions described by Article 41 mainly state what actions consti-
tute an offense under the Act and occasionally provide possible punishments,
such as imprisonment upon conviction, fines, or both.67
65. Article 9 (license committees and other committees), Article 10 (licensing procedure), Article 11
(licenses for treatment, storage and research), Article 12 (general license conditions), Article 13 (conditions of
licenses for treatment), Article 14 (conditions of storage licenses), Article 15 (conditions of research licenses),
Article 16 (grant of license), Article 17 (person responsible/supervises the activities authorized by a license),
Article 18 (revocation and variation of license), Article 19 (procedure for refusal, variation or revocation of
license), Article 20 (appeal to Authority against determinations of license committee), Article 22 (temporary
suspension of license). Human Fertilization and Embryology Act 1990 (c.37), http://www.hmso.
gov.uk/acts/actsl990/Ukpga_19900037_en_2.htm#mdiv8 (November 1, 1990).
66. Id. at Article 41. It states:
(1) A person who- (a) contravenes section 3(2) or 4(l)(c) of this Act, or (b) does any-
thing which, by virtue of section 3(3) of this Act, cannot be authorised by a licence, is
guilty of an offence and liable on conviction on indictment to imprisonment for a term
not exceeding ten years or a fine or both. (2) A person who-(a) contravenes section
3(1) of this Act, otherwise than by doing something which, by virtue of section 3(3) of
this Act, cannot be authorised by a licence, (b) keeps or uses any gametes in contraven-
tion of section 4(1)(a) or (b) of this Act, (c) contravenes section 4(3) of this Act, or (d)
fails to comply with any directions given by virtue of section 24(7)(a) of this Act, is
guilty of an offence. (3) Ifa person--(a) provides any information for the purposes of
the grant of a licence, being information which is false or misleading in a material par-
ticular, and (b) either he knows the information to be false or misleading in a material
particular or he provides the information recklessly, he is guilty of an offence. (4) A
person guilty of an offence under subsection (2) or (3) above is liable-(a) on convic-
tion on indictment, to imprisonment for a term not exceeding two years or a fine or
both, and (b) on summary conviction, to imprisonment for a term not exceeding six
months or a fine not exceeding the statutory maximum or both. (5) A person who dis-
closes any information in contravention of section 33 of this Act is guilty of an offence
and liable- (a) on conviction on indictment, to imprisonment for a term not exceeding
two years or a fine or both, and (b) on summary conviction, to imprisonment for a term
not exceeding six months or a fine not exceeding the statutory maximum or both. (6) A
person who- (a) fails to comply with a requirement made by virtue of section 39(1)(b)
or (2)(b) or 40(2)(b)(ii) or (5)(b) of this Act, or (b) intentionally obstructs the exercise of
any rights conferred by a warrant issued under section 40 of this Act, is guilty of an of-
fence. (7) A person who without reasonable excuse fails to comply with a requirement
imposed by regulations made by virtue of section 10(2)(a) of this Act is guilty of an of-
fence. (8) Where a person to whom a licence applies or the nominal licensee gives or
receives any money or other benefit, not authorised by directions, in respect of any sup-
ply of gametes or embryos, he is guilty of an offence. (9) A person guilty of an offence
under subsection (6), (7) or (8) above is liable on summary conviction to imprisonment
for a term not exceeding six months or a fine not exceeding level five on the standard
scale or both. (10) It is a defence for a person ("the defendant") charged with an offence
of doing anything which, under section 3(1) or 4(1) of this Act, cannot be done except
in pursuance of a licence to prove--(a) that the defendant was acting under the direction
of another, and (b) that the defendant believed on reasonable grounds-(i) that the other
person was at the material time the person responsible under a licence, a person desig-
nated by virtue of section 17(2)(b) of this Act as a person to whom a licence applied, or
a person to whom directions had been given by virtue of section 24(9) of this Act, and
(ii) that the defendant was authorised by virtue of the licence or directions to do the
thing in question. (11) It is a defence for a person charged with an offence under this
Act to prove-(a) that at the material time he was a person to whom a licence applied or
to whom directions had been given, and (b) that he took all such steps as were reason-
able and exercised all due diligence to avoid committing the offence.
67. Id.
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The Act contains four additional Schedules, each of which expounds
on a specific area governed by the Act that requires further elaboration.
Schedule 1 addresses supplementary administrative provisions regarding the
HFEA.68 Schedule 2 sets out specific requirements regarding licensing ac-
tivities.69 Schedule 3 discusses the various forms of informed consent as
related to the Act.7" Schedule 4 delineates any amendments that are related
to or affect other United Kingdom legislation. 7' Any amendments to the Act
addressing stem cell research would be primarily under Schedule 2 regarding
what activities may be licensed under the Act.
In addition to the specific activities required for the granting of a li-
cense under the HFEA as enumerated in Schedule 2, the Act also provides
general restrictions on the use or storage of embryos regardless of their sub-
sequent use. Article 3 of the Act sets out general prohibitions regarding em-
bryos. Article 3(1) states that "[n]o person shall-(a) bring about the crea-
tion of an embryo, or (b) keep or use an embryo, except in the pursuance of a
license., 72 The only way embryos may be kept or created in the United
Kingdom, for research or treatment, is by means of a license granted by the
HFEA for such a purpose. The licensing procedure of the HFEA provides an
exception to the overall ban in the United Kingdom against creating, keep-
ing, and using embryos. The approach by the United Kingdom may seem to
be progressive, but such progression is permitted pursuant to strict and com-
prehensive legislative regulation. Article 3(2) states that "no person shall
place in a woman-(a) a live embryo other than a human embryo, or (b) any
live gametes other than human gametes., 73 This restriction does permit plac-
ing human embryos in women resulting from IVF, which was the main ini-
tial purpose of this Act. When taken with Article 3(1) above, an embryo
cannot be created and placed into a woman unless the creation of that em-
bryo is in pursuance with a license granted by the HFEA for that express
purpose. Article 3(3) delineates four situations that cannot be authorized by
a license: (a) keeping or using an embryo after the appearance of the primi-
tive streak; (b) placing an embryo in an animal; (c) keeping or using an em-
bryo in any circumstances in which regulations prohibit its keeping or use,
or; (d) replacing a nucleus of a cell of an embryo with a nucleus taken from a
cell of any person, embryo or subsequent development of an embryo. 74 Arti-
68. Human Fertilization and Embryology Act 1990 (c.37) Schedule 1, at http://www.hmso.
gov.uklacts/actsl990/Ukpga 19900037 en 3.htm#sdivl (Sept. 20,2000).
69. Id. at Schedule 2.
70. Id. at Schedule 3.
71. d. at Schedule 4.
72. Human Fertilization and Embryology Act 1990 (c.37) Article 3(1)(a) & (b), at
http://www.hmso.gov.uk/acts/acts1990/Ukpga_19900037 en 2.htm#mdiv8 (Nov. 1, 1990).
73. "(2) No person shall place in a woman- (a) a live embryo, or (b) any live gametes other than human
gametes." Id. at Art. 3(2)(a)-(b).
74. "(3) A licence cannot authorise- (a) keeping or using an embryo after the appearance of the primitive
streak, (b) placing an embryo in any animal, (c) keeping or using an embryo in any circumstances in which
regulations prohibit its keeping or use, or (d) replacing a nucleus of a cell of an embryo with a nucleus taken
from a cell of any person, embryo or subsequent development of an embryo." Id. atArt. 3(3).
2002]
Journal of Legislation [Vol. 28:2
cle 3(4) defines the primitive streak, as mentioned in Article 3(a), as being
approximately equivalent to fourteen days, beginning with the day when the
gametes75 are mixed but "not counting any time during which the embryo is
stored. 76 This requirement puts a developmental cap on what embryos may
be kept or used in pursuance of a. license granted by the HFEA. Hence, not
only must any use or storage of an embryo be in pursuance of an activity
permitted and licensed by the HFEA, the embryos used must also be of a
specific developmental stage.
These general prohibitions set the foundation for the more specific
licensing guidelines and requirements enumerated in Schedule 2 of the Act.
Article 1(1) of Schedule 2 sets out when licenses for treatment can be
granted .77 Licenses for treatment generally seem to refer to procedures re-
lated to in vitro fertilization, but Article l(1)(g) stipulates a catchall provi-
sion that also permits treatment licenses for any "such other practices as may
be specified in, or determined in accordance with, regulations. 78 Article
1(3) also discusses other more general regulations regarding the granting of
licenses, such as a license cannot "authorise any activity unless it appears to
the Authority to be necessary or desirable for the purpose of providing
treatment services."79 This concept of "necessary or desirable" appears again
in Schedule 2 and provides an interesting and perhaps problematic require-
ment regarding treatment and research. Article 1(4) stipulates another prohi-
bition regarding activities authorized by a license, and Article 1(5) places a
five-year time limit on the validity of licenses granted for purposes under
Article 1L" Article 2 of Schedule 2 addresses licenses for storage of em-
bryos.8' Article 3(1) of Schedule 2 addresses situations where licenses can
75. Gametes refer to human reproductive cells, such as egg and sperm.
76. "(4) For the purposes of subsection (3)(a) above, the primitive streak is to be taken to have appeared
in an embryo not later than the end of the period of 14 days beginning with the day when the gametes are
mixed, not counting any time during which the embryo is stored." Human Fertilization and Embryology Act,
supra note 72, at Art. 3(4).
77. A licence under this paragraph may authorize any of the following in the course of provid-
ing treatment services- (a) bringing about the creation of embryos in vitro, (b) keeping
embryos, (c) using gametes, (d) practices designed to secure that embryos are in a suitable
condition to be placed in a woman or to determine whether embryos are suitable for that
purpose, (e) placing any embryo in a woman, (f) mixing sperm with the egg of a hamster,
or other animal specified in directions, for the purpose of testing the fertility or normality
of the sperm, but only where anything which forms is destroyed when the test is complete
and, in any event, not later than the two cell stage, and (g) such other practices as may be
specified in, or determined in accordance with, regulations.
Human Fertilization and Embryology Act, 1990, c. 37, Art. 1(1), sched. 2 (Eng.), at
http://www.hmso.gov.uk/acts/acts1990/Ukpga_19900037_en4.htm#sdiv2, (last modified Sept. 20, 2000).
78. Id. at Art. l(1)(g).
79. Id. at Art. 1(3).
80. "(4) A licence under this paragraph cannot authorise altering the genetic structure of any cell while it
forms part of an embryo. (5) A licence under this paragraph shall be granted for such period not exceeding five
years as may be specified in the licence." Id. at Art. 1(4)-(5).
81. Id. atArt. 2. It states:
(1) A licence under this paragraph or paragraph 1 or 3 of this Schedule may authorise the
storage of gametes or embryos or both. (2) Subject to the provisions of this Act, a licence
authorising such storage may be granted subject to such conditions as may be specified in
the licence and may authorise storage in such manner as may be so specified. (3) A li-
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be granted for research purposes. Any amendment regarding stem cell re-
search would be incorporated under Article 3(2) of Schedule 2. This article
states that the HFEA cannot license human embryonic research of any kind
unless it appears to the HFEA that such research is "necessary or desirable"
for the following purposes: (a) promoting advances in the treatment of infer-
tility; (b) increasing knowledge about the causes of congenital disease; (c)
increasing knowledge about the causes of miscarriages; (d) developing more
effective techniques of contraception; (e) developing methods for detecting
the presence of gene or chromosome abnormalities in embryos before im-
plantation.83
As with the article addressing treatment licenses, there is a catchall
provision in Article 3(2) stating that research licenses may be granted "for
other purposes as may be specified in regulations. 84 Article 3(3) further
qualifies this last provision by stating "purposes may only be specified with
a view to the authorisation of projects of research which increase knowledge
about the creation and development of embryos, or about disease, or enable
such knowledge to be applied."85 Article 3(6) also prohibits the granting of a
license unless the HFEA is satisfied that any proposed use of embryos is
"necessary for the purposes of the research., 86 This "necessary" requirement
needed for any research license granted by the HFEA narrows the scope of
what research projects related to human embryos can be licensed under the
Act. Despite this restricted approach to research licensing, it does provide
the HFEA with discretion in a rapidly progressing field of biotechnology and
medicine. Perhaps the necessity requirement allows the HFEA to consider
new research ventures that may not have been directly considered by the
formulators of the Act while amendments that directly address such new
developments are being created; it permits them to stay with the general
"feel" of the Act while trying to legislate regarding new technologies.
How does this relate to stem cell research? What if a company or re-
search facility wanted a license to utilize in vitro fertilization embryos for
the creation of stem cell lines? This is not directly provided for in the five
purposes stated in Article 3(2), and it has been argued that such research
does not fall within the scope of the Act. But the "necessary" requirement
demands that the HFEA only permit research, whether it falls under a new
cence under this paragraph shall be granted for such period not exceeding five years as
may be specified in the licence.
Id.
82. "(1) A licence under this paragraph may authorise any of the following- (a) bringing about the
creation of embryos in vitro, (b) keeping or using embryos, for the purpose of a project of research specified in
the license. " Human Fertilization and Embryology Act, 1990, c. 37, Art. 3(1), sched. 2 (Eng.), at
http://www.hmso.gov.uk/acts/acts1990/Jkpga_19900037_en_4.htm#sdiv2, (last modified Sept. 20, 2000).
83. 1d. at Art. 3(2).
84. Id.
85. Id. at Art. 3(3).
86. Article 3(6) states: "No licence under this paragraph shall be granted unless the Authority is satisfied
that any proposed use of embryos is necessary for the purposes of the research.." Id. at Art. 3(6).
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regulation that is not yet part of the Act or a currently existing one that it
deems necessary. This allows the HFEA control over new research ventures
that the legislative process may not have addressed yet. It also provides a
precedent as to what new research ventures the HFEA might consider to be
"necessary" and which ones they do not, thus providing direction for subse-
quent legislation but also informing researchers what work will thus be per-
mitted and what will not. Any legislative provisions addressing stem cell
research would focus mainly on the research potential and use of stem cells
and any changes would likely be directed at amending Article 3 by adding
two new categories under Article 3(2). But how did these new concerns
come to the attention of the HFEA? Stem cell research was an obscure
branch of cell and developmental biology and did not garner a significant
amount of attention. After the successful cloning of the sheep, Dolly, in
199687, interest in the feasibility of cell nuclear replacement and other related
procedures and research, including stem cell research, grew dramatically and
the Act had to be re-examined in order to provide some sort of legislative
scheme for these rapidly developing technologies.
In 1998, the HFEA and the Human Genetics Advisory Commission
(HGAC) examined the issues arising from these developments and recom-
mended in their report that the Secretary of State for Health consider amend-
ing Schedule 2 to include two new purposes for which the HFEA might issue
research licenses.88 As a result of this suggestion by the HFEA and the
HGAC, an expert committee was created to address this issue in 1999 and
initially recommended that research involving embryos, whether the em-
bryos were created by in vitro fertilization or cell nuclear transfer, would
"increase understanding about human disease and disorders and their cell-
based treatments" and "should be permitted subject to the controls in the
Human Fertilization and Embryology Act 1990.""9 In response to the report
drawn up by this expert committee, the Parliament put forth draft regulations
that extended the purposes for which human embryonic research was law-
fully permitted. 9 These regulations, termed the Human Fertilization and
Embryology (Research Purposes) Regulations 2001 were passed in the
House of Commons on December 19, 20009' and by the House of Lords on
87. Dolly was the first mammal ever to be cloned from an adult mammal cell by means of cell nuclear
transplantation. The announcement of Dolly's birth brought into focus the possibility of cloning humans and
the accompanying moral, ethical, and legal implications. H. R. REP. No. 107-170, at
http://www.house.gov/judiciary/egreports.htm, (July 27, 2001).
88. The two new purposes are the development of methods of therapy for mitochondrial disease and the
development of therapeutic treatments for diseased or damaged tissues or organs. Stem Cell Research and
Regulations under the Human Fertilization and Embryology Act 1990 (HC Library Research Paper (2000-01)
no. 00/93), at 10, at http://www.parliament.uk/commons/lib/research/rp2000/rpOO-093.pdf, (Dec. 13, 2000).
89. Department of health, Donaldson Report on Stem Cell Research: Medical Progress with Responsibil-
ity 33, at http://www.doh.gov.uk/cegc/stemcellreport.htm (Aug. 16, 2000). (on file with author)
90. Stem Cell Research and Regulations under the Human Fertilization and Embryology Act 1990, supra
note 88, at 10- 1l.
91. House of Lords, Select Committee on Stem Cell Research Report, Chapter 1 § 1.10, at
http://www.publications.parliament.uk/pa/ld200102/ldselect/ldstem/3/830 1/htm (Feb. 13, 2002).
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January 22, 2001.92 The Regulations added three new purposes to the Act:
first, "increasing knowledge about the development of embryos," second,
"increasing knowledge about serious disease," and third, "enabling any such
knowledge to be applied in developing treatments for serious disease." 3
The regulatory system established by the Act has worked quite well
and the HFEA is considered the foundation for the entire regulatory system.
94
According to the House of Lords Select Committee on Stem Cell Research
(the Committee), 95 the work of the HFEA is highly regarded in both the
United Kingdom and abroad and commands the full confidence of the scien-
tific and medical research community. 96 The HFEA also has been instrumen-
tal in addressing and reassuring public concerns about the effectiveness and
sensitivity required regarding regulation in such an emotionally and ethically
charged area of public policy.97 There have also been few legal challenges to
the rulings and media criticism has focused on the strictness of the rulings
rather than their laxity.98 The Act provides a solid legislative and regulatory
framework for Parliament to work in regarding new legislation and amend-
ments addressing stem cell research and human cloning. In terms of human
embryo research, the Committee stipulated in the report that they had not
received evidence of any instance in which the HFEA's handling of applica-
tions for licenses under the Act had been the subject of criticism.99
The Act's main focus is reproductive medicine, and the new pro-
posed regulations require the HFEA to consider license applications for re-
search addressing a wide variety of serious illnesses as well as the basic re-
search underlying such research.0 ° The Committee also recognized the rapid
development and potential of adult stem cell research and the possibility that
adult stem cell research could render further research on ES cells unneces-
sary.1"1 The Act does provide for a built-in legislative brake on research on
92. Id.
93. Id.
94. House of Lords, Select Committee on Stem Cell Research Report
Chapter 8 § 8.1, at http://www.publieations.parliament.uk/paId200102/Idselect/Idstem/83/8301 htm (Feb. 13,
2002).
95. The House of Lords passed a motion on March 7, 2001 appointing the Committee "to consider and
report on the issues connected with human cloning and stem cell research arising from the Human Fertilisation
and Embryology (Research Purposes) Regulations." The main question underlying the appointment of the
Committee was "whether the extension of the purposes in the 2001 Regulations is justified" and the Commit-
tee has examined issues such as "(a) the potential benefits of stem cell research; (b) whether, in the current
state of scientific knowledge, there are satisfactory alternatives to research on human embryos; (c) the status of
the early embryo; (d) the distinctions to be drawn, if any, between the use for research of "surplus" embryos
(i.e. embryos left over from lVF treatment), of embryos created by IVF, and of embryos created by CNR; (e)
the commercial interests involved; (I) the international context to the debate; (g) the possible need for further
legislation; and (h) the possible need for further provision for the custody and regulation of stem cell "lines"
derived from early embryos." House of Lords. Select Committee on Stem Cell Research Report, supra note
91, at § 1.15 & 1.19.
96. House of Lords, Select Committee on Stem Cell Research Report, supra note 91, at § 8.1.
97. Id.
98. Id.
99. Id. at § 8.2.
100. Id. at § 8.3.
101. House of Lords, Select Committee on Stem Cell Research Report, supra note 94, at § 8.4.
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human embryos, since each proposal for a license has to be reviewed in or-
der to determine that the same results could not be achieved by other re-
search.1"2 If the proposed 2001 Regulations did broaden the scope of the Act
to permit applications for research involving embryonic stem cells, the regu-
lations would operate in concert with the previously existing legislative re-
strictions already present in the 1990 Act. Since adult stem cell research has
advanced at a rapid pace, the Committee recognized and emphasized the
need to stay abreast of such developments. The Committee suggested that
the UK government should review further developments regarding adult
stem cells as well as stem cell banks. 10 3
The 2001 Regulations were drafted to include research using stem
cells from embryos created by in vitro fertilization and cell nuclear replace-
ment based on the idea that embryos created by cell nuclear transfer should
be considered embryos and fall under the scope of the Act. This approach
was challenged in 2001 by judicial proceedings brought by the director of a
pro-life organization that was opposed to human cloning. 10 4 The director
sought a declaration stating that human embryos created by cell nuclear re-
placement fell outside the definition of an embryo in the Act.105 The Gov-
ernment argued that an embryo created by cell nuclear transfer was "mor-
phologically and functionally indistinguishable from an embryo produced by
fertilisation.' ' 10 6 The Queen's Bench Division held that an organism created
by cell nuclear transfer without fertilization was not an embryo within the
definition used in the Act.0 7 The court also found that using the definition
set forth by the Government would permit "an impermissible rewriting and
extension of the definition."10 8 The court awarded the declaration and stated
that organisms produced by cell nuclear replacement were not subject to
regulation under thel990 Act.109 As a result of this decision, the concern
was that by removing embryos produced by means of cell nuclear replace-
ment from the scope of the 1990 Act, a loophole now existed for reproduc-
tive cloning that was virtually unregulated. The HFEA thus would not be
able to implement a ban on reproductive cloning by refusing to license an
application for this purpose.10 On November 21, 2001, Parliament passed
the Human Reproductive Cloning Bill in response to the concerns regarding
102. Id.
103. The HFEA, along with other agencies, has decided that there is a need for a stem cell bank that would
provide scientists with access to embryonic stem cell lines "of guaranteed purity and provenance, and from
sources which operate ethically-approved standards." Id. at § 8.26.
104. R (on the application of Quintavalle) v. Secretary of State for Health, LEXIS 2001 EWHC Admin 918
(Q.B. 2001).
105. Id.
106. Id.
107. Id.
108. Id.
109. R (on the application of Quintavalle) v. Secretary of State for Health, LEXIS 2001 EWHC Admin 918
(Q.B. 2001).
110. Explanatory Notes to Human Reproductive Cloning Act, 2001, c. 23, 3, at http://www.uk-
legislation.hmso.gov.uk/acts/acts2001 .htm (Nov. 22, 2001).
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reproductive cloning in the United Kingdom.'11 The purpose of the bill is to
prevent human reproductive cloning by making it a criminal offense to place
in the womb of a woman a human embryo that has been created other than
by fertilization." 2 Combined with the 1990 Act and the 2001 Regulations
addressing stem cell research, this bill addressing reproductive cloning
rounds out the United Kingdom legislative scheme addressing stem cell re-
search and cloning and provides a solid and workable foundation for future
legislation.
SECTION III: THE UNITED STATES
Unlike the United Kingdom, in the United States has not yet devel-
oped, a uniform national legislative approach to stem cell research has not
yet been developed and the situation is ambiguous. Prior to August 2001,
there was no federal funding for stem cell research and such research was
carried out with private funds. There are currently no clear prohibitions or
regulatory restrictions on private sector research regarding stem cell research
and human cloning." 3 The August 2001 directive only refers to the require-
ments for the receipt of federal funds, not the prohibition of various forms of
stem cell and cloning research.
The August 2001 directive provided limited federal funds for stem
cell research; this funding, monitored by the National Institutes of Health,
was allocated for research on stem cells that have already been extracted
from embryos."' This policy excludes the use of leftover embryos from in
vitro fertilization treatments from being used by research firms that intend to
request federal funds. Research on adult stem cells and umbilical cord stem
cells are fully funded whereas research that involves leftover frozen embryos
from in vitro fertilization treatments does not receive federal funding." 5 The
only aspect of research using frozen in vitro fertilization embryos that is ap-
proved for federal funding is research conducted on existing stem cell lines
that were obtained from leftover in vitro fertilization embryos; the embryos
used to create these lines also had to be donated by willing couples that did
not receive monetary compensation for their donation. 116 No federal money
will be allocated for research facilities that use donor embryos or cloned
embryos. 17
The federal funding policy does not permit the collection of sperm
and egg donations specifically for the purpose of developing stem cells for
111. Id.
112. Id. at 6.
113. H.R REP. No. 107-170, (2001), at http://www.house.gov/judiciary/legreports.htm.
114. Mitch Frank, How Bush Got There, TIME MAGAZINE, Aug. 20, 2001, at 18.
115. 1d.
116. Id.
117. Id.
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research." 8 Scientists argued that it was a more honest approach to create
them for research, but it was perceived as a step towards a slippery slope
leading to human cloning." 9 Again, this option is not closed off to private
funding and most likely will continue, especially if the already existing stem
cell lines prove to be insufficient. 2 ° Cloned embryos, whether created for
therapeutic or reproductive purposes, will not be eligible for federal funds.'
The House of Representatives passed a bill in November 2001 banning all
cloning procedures, 22 and if the Senate follows suit, then all research, pri-
vate as well as public and regardless of funding sources, involving any form
of cloning will be illegal. 123  The President favors a ban that includes all
forms of cloning, similar to the House of Representatives bill, whilst scien-
tific advisory panels, such as the National Academy of Sciences Advisory
Panel, tend to favor a ban that only includes reproductive cloning but not
therapeutic cloning. 24 The Senate, however, was unable to reach a consen-
sus regarding cloning at this time.'25
The federal funding policy delineates a limited precedent for legisla-
tive development addressing stem cell research. At the time of the an-
nouncement of the policy, various bills were circulating in the House of Rep-
resentatives and the Senate addressing stem cell research, cloning and their
relationship to each other. Some of these bills address solely stem cell re-
search while others attempt to prohibit cloning while protecting stem cell
research. The balance has become increasingly difficult, especially in light
of the research connections between human cloning and stem cell research
and the possibility of a legislative ban on cloning in the United States. There
is no current legislative starting point in the United States when it comes to
regulating embryonic research. Various federal administrative bodies, such
as the Food and Drug Administration,2 6 have been suggested in various bills
118. Id.
119. Frank, supra note 114, at 18.
120. Id.
121. Id.
122. Rick Weiss & Ceci Connolly, Experts urge Ban on cloned Babies but Panel Backs Embryo Research,
WASH. POST, available at http://bioethics.net/news/html/cloning.php (Jan. 19, 2002).
123. Frank, supra note 114, at 18.
124. Weiss & Connolly, supra note 122.
125. Helen Dewar, Anti-Cloning Bills Stall in Senate; Vote Unlikely Soon, WASH. POST, available at
http://www.washingtonpost.com/wp-dyn/nation/specials/science/cloning/index.html (June 14,2002).
126. The Food and Drug Administration (FDA) announced that it has the authority to regulate human
cloning but that authority has been questioned by numerous experts and still remains unclear. According to
the FDA, the authority comes partially from Public Health Services Act (PHS), which gives the FDA the
"power to regulate 'biological products' that are used to treat medical conditions." The FDA claims that a
human clone resulting from cell nuclear replacement is a 'biological product' intended to treat a medical
condition, that condition being infertility. The FDA also states that it can regulate human cloning under the
Food, Drug and Cosmetic Act because human clones resulting from cell nuclear replacement fall under the
definition of"drugs." That act defines drugs as "articles" intended to affect the structure or any function of the
body. The FDA considers a human clone as an "article" that affects the structure and functions of a woman's
body by making her pregnant and would be subject to investigational new drug application requirements under
the Food, Drug and Cosmetic Act. H.R. REP. NO. 107-170, at 2 (2001), at http://www.house.
gov/judiciary/legreports.htm.
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as starting points for the development of a regulatory regime regarding stem
cell research and cloning.
The current legislative situation in the United States is very confus-
ing and it will be some time before a comprehensive legislative regime exists
addressing stem cell research and human cloning. The laws addressing the
use of embryos, in both stem cell research and cloning, create a patchwork of
legislation that makes it increasingly difficult to keep up with the rapidly
changing pace of scientific technology. The statutory and regulatory scheme
in the United Kingdom, on the other hand, acts as a starting point for the
development of regulations for stem cell research and cloning.
A significant number of the bills under consideration by Congress
address various aspects of stem cell research administration, storage, and
development. The most recent bill, 2002 H.R. 4011, deals with an adminis-
trative need arising from the August 9, 2001 presidential stem cell direc-
tive. 12' The main aim of this bill, introduced in the House of Representatives
on March 20, 2002, is to establish the Stem Cell Research Board that will
conduct research on the effects of the August 9, 2001 presidential directive
regarding stem cell research. 128  The Stem Cell Research Board, as estab-
lished by the bill, would be charged with conducting research, 129 making
recommendations to Congress regarding any legislation needed to address
aspects such as funding or research,13 conducting public forums addressing
the status of federal funding,'31 and developing its own standards of con-
duct.132  The primary focus of the Stem Cell Research Board seems to be
centered on the issue of federal funding and how such funding shall be legis-
127. "A bill to establish the Stem Cell Research Board to conduct research on the effects of the President's
August 9, 2001, stem cell research directive, and for other purposes." Science of Stem Cell Research Act, H.R.
4011, 107th Cong. (2002), LEXIS 2002 107th CONG US HR 4011.
128. "Section 3 Establishment. There is established in the legislative branch a bipartisan commission to be
known as the Stem Cell Research Board." Id.
129. Section 4 Duties. (a) Research. The Board shall conduct research on the following: (1)
The effects, whether positive or negative, of the President's August 9, 2001, stem cell re-
search directive, on the following: (A) The progress of advances in curing or remediating
diseases or other medical conditions, including AIDS, Alzheimer's disease, anemia, arthri-
tis, birth defects, blindness, brain injury, cancer, deafhess, diabetes heart disease, kidney
disease, liver disease, Lou Gehrig's disease, lung disease, multiple sclerosis, muscular dys-
trophy, Parkinson's disease, severe bums, sickle cell anemia, spinal cord injury, and
stroke. (B) The progress of improvements in successful organ transplantation. (C) The
development of any medical technology, including any halt or delay in such development.
(D) Basic scientific research. (2) The effect of limiting Federal funding on the private
stem cell research sector. (3) All aspects of the funding process of the National Institutes
of Health for human adult and embryonic stem cell research.
Id.
130. "Section 4 Duties (b) Recommendations. In reports submitted under section 9, the Board shall make
recommendations to the Congress on any legislation needed to reduce any inefficiencies in Federal funding of
human embryonic stem cell research or to facilitate a more timely implementation of such research." Id.
131. "Section 4 Duties. (c) Public Forums. The Board shall conduct periodic public forums to review the
status of stem cell research funding by the National Institutes of Health." Id.
132. "Section 4 Duties. (d) Standards of Conduct. The Board shall develop its own standards of conduct in
consultation with the Committee on Standards of Official Conduct of the House of Representatives or the
Select Committee on Ethics of the Senate, as applicable." H.R. 2863, 107th Cong. (2001), LEXIS 2001 107th
CONG US HR 2863.
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lated and implemented. The bill is an attempt to create a supervisory body to
oversee the appropriation of federal funding for stem cell research and to
make legislative recommendations in furtherance of that goal. An earlier
bill, 2001 H.R. 2863,' has a similar aim to H.R. 4011 but with a more gen-
eral scope. The bill, the Cell Development Research Act of 2001, directs the
"Secretary of Health and Human Services to establish and maintain a panel
to provide expert scientific recommendations in the field of cell develop-
ment.', 134  Instead of focusing primarily on advisory panels exclusively for
stem cell research and development, as in H.R. 4011, this bill extends advi-
sory panels to general cell development. Section 3 of the H.R. 2863 dis-
cusses the establishment of a cell development advisory panel by amending
Section 505 of the Food, Drug, and Cosmetic Act.'35 The Secretary of
Health and Human Services will create and maintain a single panel in the
Food and Drug Administration whose job will be to provide expert scientific
advice to the Secretary that includes recommendations "regarding any clini-
cal investigation of a drug developed as a result of research in the field of
embryology."'36 The bill also defined the field of cell development as in-
cluding embryonic stem cell research, therapeutic cloning, preimplantation
genetic diagnosis and early developmental biology. 137  What is beneficial
about the proposal put forth in H.R. 2863 is that it recognizes the intercon-
133. Id.
134. Id.
135. Id.
Section 3 Establishment of Cell Development Advisory Panel Subsection (n) of section
505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C 355(n)) is amended by add-
ing at the end the following: (9) Cell development advisory panel- (A) Establishment-
The Secretary shall establish and maintain under this subsection a single panel in the
Food and Drug Administration to provide expert scientific advice and recommendations
to the Secretary in the field of cell development, including advice and recommendations
regarding any clinical investigation of a drug developed as a result of research in the
field of embryology and any approval for marketing of such a drug under this section or
section 351 of the Public Health Service Act. (B) Promotion of Research - Such panel
shall make policy recommendations with the goal of promoting research in the field of
cell development. (C) Prohibition- Such panel shall not make any recommendation re-
garding the practice of fertility medicine. (D) Field of Cell Development- For purposes
of this paragraph, the term 'field of cell development' includes embryonic stem cell re-
search, therapeutic cloning, preimplantation genetic diagnosis, and early developmental
biology.
Id.
136. Id.
Section 3 Establishment of Cell Development Advisory Panel ... (9) Cell development
advisory panel.. .(A) Establishment - The Secretary shall establish and maintain under
this subsection a single panel in the Food and Drug Administration to provide expert sci-
entific advice and recommendations to the Secretary in the field of cell development, in-
cluding advice and recommendations regarding any clinical investigation of a drug de-
veloped as a result of research in the field of embryology and any approval for marketing
of such a drug under this section or section 351 of the Public Health Service Act.
Id.
137. "Section 3 Establishment of Cell Development Advisory Panel (9) Cell Development Advisory Panel
(D) Field of Cell Development-For purposes of this paragraph, the term 'field of cell development'
includes embryonic stem cell research, therapeutic cloning, preimplantation genetic diagnosis, and early de-
velopmental biology." H.R. 2863, 107th Cong, (2001), LEXIS 2001 107th CONG US HR 2863.
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nectedness between cell development, stem cell research, and therapeutic
cloning. Perhaps having two different advisory boards under different legis-
lative schemes is beneficial by providing various perspectives on a challeng-
ing issue. Yet the same difficulty that plagues the United States system gen-
erally is also a concern here at the introductory legislative level. Creating
advisory boards that could provide useful expert advice in separate legisla-
tive schemes with no real overriding body could add to the confusion and
lack of direction already complicating the United States system.
Some bills focus more on providing more specific guidelines and
definitions for stem cell research with the overall purpose of clarifying and
implementing the 2001 presidential directive. H.R. 2059 was brought before
the House of Representatives on June 5, 2001, to amend the Public Health
Service Act in order to provide for human embryonic stem cell generation
and research.138 The purpose of the bill is to delineate what means of genera-
tion and uses of human embryonic stem cells can be funded, supported or
conducted with federal funding. 39 H.R. 2059 states that in order to carry out
stem cell research, human embryonic stem cells used for such research can
only be derived from embryos that have been donated from in vitro fertiliza-
tion clinics. 4 ' These clinics also have to comply with two specified condi-
tions before such embryos can be utilized for research. First, before the em-
bryos could be considered for donation, such embryos could never have been
intended to be implanted in a woman and thus were going to be discarded.'4 '
138. "A bill to amend the Public Health Service Act to provide for human embryonic stem cell generation
and research." Stem Cell Research Act of 2001, H.R. 2059, 107th Cong. (2001), LEXIS 2001 CONG US HR
2059.
139. Section 2 Human Embryonic Stem Cell Generation and Research. Part H of the Title IV of the
Public Health Service Act (42 U.S.C. 289 et seq.) is amended by inserting after section 498B the following:
Section 498C. Human Embryonic Stem Cell Generation and Research. (a) In General-
Notwithstanding any other provision of law, the Secretary may only conduct, support, or
fund research on human embryos for the purpose of generating embryonic stem cells and
utilizing stem cells that have been derived from embryos in accordance with this section.
(b) Sources of Embryonic Stem Cells- For purposes of carrying out research under sub-
section (a), the human embryonic stem cells involved shall be derived only from em-
bryos that have been donated from in-vitro fertilization clinics after compliance with the
following: (1) Prior to the consideration of embryo donation and through consultation
with the progenitors, it is determined that the embryos will never be implanted in a
woman and would otherwise be discarded. (2) The embryos are donated with the written
informed consent of the progenitors. (c) Restrictions-(1) In General-The following
restriction shall apply with respect to human embryonic stem cell research conducted or
supported under subsection (a): (A) The research involved shall not result in the crea-
tion of human embryos. (B) The research involved shall not result in the reproductive
cloning of a human being. (2) Prohibition - (A) In General- It shall be unlawful for any
person receiving Federal funds to knowingly acquire, receive, or otherwise transfer any
human embryos for valuable consideration if the acquisition, receipt, or transfer affects
interstate commerce. (B) Definition- In subparagraph (A), the term 'valuable considera-
tion' does not include reasonable payments associated with transportation, transplanta-
tion, processing, preservation, quality control, or storage.
Id.
140. "(b) Sources of Embryonic Stem Cells-For purposes of carrying out research.. ihe human embry-
onic stem cells involved shall be derived only from embryos that have been donated from in vitro fertilization
clinics after compliance with the following .. ." Id.
141. "(b)(1): Prior to the consideration of embryos donation and through consultation with the progenitors,
it is determined that the embryo will never be implanted in a woman and would otherwise be discarded." Id.
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Second, the embryos could not be donated without the written informed con-
sent of the donators. 4 2 This bill establishes restrictions on the proposed re-
search, including a blanket prohibition on the creation of human embryos for
the purposes of research and a specific prohibition on the reproductive clon-
ing of a human being. 4 3  The bill also provides for further restrictions that
prevent human embryos from being knowingly used or transported for valu-
able consideration in a way that affects interstate commerce.' In addition,
the bill requires the Secretary, along with the director of the National Insti-
tute of Health, to issue guidelines that would include rules governing the
derivation of stem cells from donated embryos.'45 The Senate has intro-
duced a related bill, 2001 S. 723, the Stem Cell Research Act of 2001.146
The main purpose of the bill is identical to H.R. 2059 and proposes to amend
the Public Health Service Act by adding another section describing in more
detail guidelines for stem cell generation and research. 47 S. 723 parallels the
text of H.R. 2059 very closely and advocates the same suggestions, such as
delineating under what conditions human embryonic stem cells can be ob-
tained. '
The Stem Cell Research for Patient Benefit Act of 2001, 2001 H.R.
2747, requires the implementation of the National Institutes of Health guide-
lines for research using human pluripotent stem cells. "9 This bill requires
the director of the National Institutes of Health to conduct or support re-
search using human pluripotent stem cells from embryos and fetal tissue in
accordance with the NIH guidelines as well as study and report to specific
congressional committees on stem cells and the effectiveness of such guide-
142. "(b)(2): The embryos are donated with the written informed consent of the progenitors." Id.
143. "(c) Restrictions-(I) In General-The following restriction shall apply with respect to human em-
bryonic stem cell research conducted or supported... (A): The research involved shall not result in the creation
of human embryos. (B) The research involved shall not result in the reproductive cloning of a human being."
Stem Cell Research Act of 2001, H.R. 2059, 107th Cong. (2001), LEXIS 2001 CONG US HR 2059.
144. "(c)(2) Prohibition-(A) In General-It shall be unlawful for any person receiving federal funds to
knowingly acquire, receive, or otherwise transfer any human embryos for valuable consideration if the acquisi-
tion, receipt, or transfer affects interstate commerce." Id.
145. "(d) Guidelines-The Secretary, in conjunction with the Director of the National Institutes of Health,
shall issue guidelines that expand on the rules governing embryonic stem cell research.. .to include rules that
govern the derivation of stem cells from donated embryos under this section." Id.
146. Stem Cell Research Act of 2001, S. 723, 107th Cong. (2001), LEXIS 2001 CONG US S 723.
147. Id.
148. Id.
A bill to amend the Public Health Service Act to provide for human embryonic stem cell
generation and research. Section 2 Human Embryonic Stem Cell Generation and Re-
search . . . (a) In General-Notwithstanding any other provision of law, the Secretary
may only conduct, support, or fund research on human embryos for the purpose of gen-
erating embryonic stem cells and utilizing stem cells that have been derived from em-
bryos in accordance with this section. (b) Sources of Embryonic Stem Cells-For pur-
poses of carrying out research under subsection (a), the human embryonic stem cells in-
volved shall be derived only from embryos that have been donated from in-vitro fertili-
zation after compliance with the following...
Id.
149. "To require implementation of the National Institutes of Health Guidelines for Research Using Human
Pluripotent Stem Cells, and for other purposes." Stem Cell Research for Patient Benefit Act of 2001, H.R.
2747, 107th Cong. (2001), LEXIS 2001 CONG US HR 2747.
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lines. 5° The bill also establishes the Biomedical Advisory Commission that
would be responsible for studying bioethical issues arising from research on
human biology and applications of such research and emerging biomedical
research, including the ethical, social, legal and regulatory issues concerning
such research and its clinical applications.' 5 ' Such a commission would be
useful, especially since it will be incorporated under the National Institutes
of Health, which is responsible for allocating federal funding. H.R. 2838, or
the New Century Health Advantage Act, is similar to H.R. 2747 in general
purpose; it also requires the Director of the National Institutes of Health to
carry out and support human pluripotent stem cell research. 152 The bill does
restrict the source of the human pluripotent stem cells to be used in the re-
search supported by the National Institutes of Health; the human pluripotent
stem cells can only be derived from human embryos created for fertility
treatments and were later not needed.'53 H.R. 2838 does not establish an
advisory board, as in H.R. 2747, but the bill does propose to repeal an earlier
150. Section 2 Implementation of National Institutes of Health Guidelines for Research using
Human Pluripotent Stem Cells: The Director of the National Institutes of Health shall
conduct or support research using human pluripotent stem cells from embryos and fetal
tissue in accordance with the National Institutes of Health Guidelines for Research Using
Human Pluripotent Stem Cells, as published in the Federal Register on August 25, 2000..
. and corrected on November 21, 2000.... Section 3(b): Report: Not later than 5 years af-
ter the date of the enactment of this Act, the Director of the National Institutes of Health
shall submit a report describing the findings and conclusions of the study to the Commit-
tee on Energy and Commerce of the House of Representatives and the Committee on
Health, Education, Labor, and Pensions of the Senate. Section 4(c) Report-The Secretary
shall ensure that, not later than 2 years after the date of the enactment of this Act, the
study to be conducted under subsection (a) is completed and a report describing the find-
ings and conclusions of the study is submitted to the Committee on Energy and Commerce
of the House of Representatives and the Committee on Health, Education, Labor and Pen-
sions of the Senate.
Id.
151. Section 5 Biomedical Advisory Commission: (a) Establishment - There is established a
commission to be known as the Biomedical Advisory Commission ... (b) Duties- (1)
Study-The Commission shall conduct studies on the following: (A): Bioethical issues
arising from research on human biology and applications of such research. (B): Emerging
biomedical research, including the ethical, social, legal, and regulatory issues concerning
such research and its clinical applications. (2) Recommendations---Based on the results of
the study, the Commission shall formulate such recommendations as it considers appro-
priate with the goal of realizing the development of effective therapies as quickly as pos-
sible, taking into account the relevant ethical, social, legal, and regulatory considerations.
(c) Membership-(1) Appointment-The Commission shall be composed of 13 members
as follows: (A) 1 member appointed by the President. (B) 3 members appointed by the
Speaker of the House of Representatives. (C) 3 members appointed by the minority leader
of the House of Representatives. (D) 3 members appointed by the majority leader in the
Senate. (E) 3 members appointed by the minority leader of the Senate. (2) Qualifications-
-The members appointed under subparagraphs (B), (C), (D), and (E) of paragraph (1)
shall include representatives from the legal, ethical, scientific, medical, patient, religious,
and industry communities.
Id.
152. "To require the Director of the National Institutes of Health to conduct or support research using
certain human pluripotent stem cells, and for other purposes." New Century Health Advantage Act, H.R. 2838,
107th Cong. (2001), LEXIS 2001 CONG US HR 2838.
153. "Section 3. Studies using Human Pluripotent Stem Cells. The Director of the National Institutes of
Health shall conduct or support research using pluripotent stem cells derived from human embryos that were
created for the purposes of fertility treatment and were in excess of the clinical need of the individuals seeking
such treatment." Id.
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prohibition regarding funding for certain human embryonic research pro-
jects.'54
Stem cell banks have been suggested as a means to maintain and
regulate sources of stem cell lines used for research. There have been bills
introduced in both the House of Representatives and the Senate addressing
stem cell banks. The Responsible Stem Cell Research Act of 2001, or H.R.
2096 provides for a national stem cell donor bank that would facilitate the
"conduct and support of research using such cells."' 55 The purpose of the
National Stem Cell Donor Bank, as set forth in H.R. 2096, is to "seek and
preserve donations of qualifying human stem cells and to make such donated
cells available for biomedical research and for therapeutic purposes."' 5 6 The
underlying point behind these banks seems to be to curtail the creation of
embryos for research purposes. If there is a nationally run stem cell bank
that collects and manages these cells then scientists can utilize the already
existing stem cell lines kept in the banks and not have any reason to create
embryos for research purposes.
Similar bills have been introduced in the Senate discussing stem cell
banks and research implementation guidelines. H.R 2096 was introduced to
deal with the potential need for a stem cell bank by directing the Secretary of
Health and Human Services to establish by contract a national stem cell do-
nor bank to preserve qualifying human stem cells and to make those stem
cells available for biomedical research.'57 The purpose of the donor bank, as
stated in the bill, is to "seek and preserve donations of qualifying human
stem cells and to make these donated cells available for biomedical re-
search."' 58 Here, qualifying human stem cells refers to human stem cells
154. "Section 4. Repeal of Prohibition of Funding for Certain Research Involving Human Embryos. Sec-
tion 510 of the Departments of Labor, Health and Human Services, and Education, and Related Agencies
Appropriations Act, 2001 (as enacted by section 1(a) of Public Law 106-554) )prohibiting the use of funds for
certain research involving human embryos), is hereby repealed." Id.
155. "To provide for a National Stem Cell Donor Bank regarding qualifying human stem cells, and for the
conduct and support of research using such cells." Responsible Stem Cell Research Act of 2001, H.R. 2096,
107th Cong. (2001), LEXIS 2001 CONG US HR 2096.
156. Id.
Section 3. National Stem Cell Donor Bank. (a) In General, The Secretary of Health and
Human Services shall by contract establish and maintain a National Stem Cell Donor
Bank.. .The purpose of the Donor Bank shall be to seek and preserve donations of qualify-
ing human stem cells and to make such donated cells available for biomedical research
and for therapeutic purposes. (b) Qualifying Human Stem Cells. For purposes of this Act,
the term 'qualifying human stem cells' means human stem cells obtained from human pla-
centas, umbilical cord blood, organs or tissues of unborn human offspring who died of
natural causes (such as spontaneous abortion.)
Id.
157. Id.
Section 3. National Stem Cell Donor Bank. (a) In General. The Secretary of Health and
Human Services shall by contract establish and maintain a National Stem Cell Donor
Bank.. .[T]he purpose of the Donor Bank shall be to seek and preserve donations of quali-
fying human stem cells and to make such donated cells available for biomedical research
and for therapeutic purposes.
Id.
158. "The purpose of the Donor Bank shall be to seek and preserve donations of qualifying human stem
cells and to make such donated cells available for biomedical research and for therapeutic purposes." Id.
[Vol. 28:2
2002] Stem Cell Legislation
"obtained from human placentas, umbilical cord blood, organs and tissues of
a living or deceased human being"'59 as well as stem cells removed from the
organs and tissues of unborn human offspring who died of natural causes.6°
In addition to bills dealing strictly with stem cell research, a few bills
have been introduced that attempt to combine stem cell research guidelines
as well as cloning prohibitions. Bills, such as 2002 S. 1893'61 and 2002 S.
2439162 attempt to prohibit human cloning while preserving "important areas
of medical research, including stem cell research."' 63  2002 S. 1893 ad-
dresses this complex relationship by amending the Public Health Services
Act by prohibiting human reproductive cloning while permitting therapeutic
cloning for research purposes.1 64 This bill generally prohibits the perform-
ance of human cloning as well as the receipt of products from somatic cell
nuclear transplantation for the purpose of human cloning. 65  The bill also
provides both criminal and civil sanctions for such actions. 166 It is notewor-
thy to mention here that the definition given in this particular bill for human
cloning refers mainly to reproductive cloning by defining it as "asexual hu-
man reproduction by implanting or attempting to implant the product of nu-
clear transplantation into a woman's uterus (or substitute for a woman's
uterus.)' ' 67  This definition makes a distinction between cloning for repro-
159. Id.
Section 3. National Stem cell Donor Bank. (b) Qualifying Human Stem Cells. For the
purposes of this Act, the term 'qualifying human stem cells' means human stem cells ob-
tained from human placentas, umbilical cord blood, organs or tissues of a living or de-
ceased human being who has been born, or organs or tissues of unborn human offspring
who died of natural causes (such as spontaneous abortion.
Id.
160. Id.
161. The purpose of this bill is to ban human cloning while protecting stem cell research and was intro-
duced into the Senate on January 24, 2002. Human Cloning and Stem Cell Research Protection Act of 2001, S.
1893, 107th Cong. (2001), LEXIS 2001 CONG US S 1893.
162. Human Cloning Prohibition Act of 2002, S. 2439, 107th Cong. (2001), LEXIS 2001 CONG US S
2439.
163. Id.
164. Human Cloning and Stem Cell Research Protection Act of 2001, S. 1893, 107th Cong. (2002), LEXIS
2001CONG US 1893.
165. Section 2 Amendment to the Public Health Services Act: (a) Prohibition:
[I]t shall be unlawful for any person or entity, public or private, in or affecting interstate
commerce-(1) to perform or attempt to perform human cloning; or (2) to ship, receive, or
import the product of nuclear transplantation for the purpose of human cloning; (d) Scien-
tific Research: Nothing in this section shall be construed to restrict areas of biomedical,
agricultural, and scientific research not specifically prohibited by this section, including
somatic cell nuclear transfer or other cloning technologies to clone molecules, DNA, cells,
and tissues.
Id.
166. Section 2 Amendment to the Public Health Services Act (b) Penalties:
(1) criminal penalties: any person or entity that is convicted of violating any provision of
this section shall be fined under this section and imprisoned not more than 10 years, or
both. (2): civil penalties: any person or entity that is convicted of violating any provision
of this section shall be subject to a civil penalty of not less than $ 1,000,000 and, in the
case of a violation that involves the derivation of a pecuniary gain greater than
$1,000,000, an amount equal to not more than the amount of such gain multiplied by 2.
Id.
167. "Section 2 Amendments to the Public Health Services Act (c) Definitions: In this section: (1): Human
cloning: the term human cloning means asexual human reproduction by implanting or attempting to implant
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ductive purposes and cloning for research or therapeutic purposes; the only
cloning that is subject to sanction, by this bill, is cloning utilized for repro-
ductive purposes. In addition to this distinction between therapeutic and
reproductive cloning, the bill also provides a research protection clause stat-
ing that "nothing in this section shall be construed to restrict areas of bio-
medical, agricultural, and scientific research not specifically prohibited by
this section, including cell nuclear transfer or other cloning technologies to
clone molecules, DNA, cells and tissues."' 68 S. 2439 also combines a prohi-
bition on reproductive cloning with a protection of research clause stating
that nothing regarding the prohibition of reproductive cloning will be under-
stood to restrict practices not expressly prohibited by the bill.169 A distinc-
tion is also made here between reproductive and therapeutic cloning 70 , as in
S. 1893, and S. 2439 also provides both civil and criminal sanctions for such
actions somewhat similar to S. 1893.' The bill also adds a section dealing
with the ethical requirements for nuclear transplantation research, such as
informed consent, institutional and board review, and protection for safety
and privacy. 17 2 These bills that only advocate a ban on reproductive cloning
and permit therapeutic cloning for research purposes did not embody the
approach the House of Representatives decided to take regarding human
cloning. The Human Cloning Prohibition Act 2001 instead required a com-
plete ban on all forms of human cloning and was passed by the House of
Representatives on July 31, 2001.173
the product of nuclear transplantation into a woman's uterus or a substitute for a woman's uterus." Id.
168. "(d) Scientific Research: Nothing in this section shall be construed to restrict areas of biomedical,
agricultural, and scientific research not specifically prohibited by this section, including somatic cell nuclear
transfer or other cloning technologies to clone molecules, DNA, cells, and tissues." Id.
169. "Section 4. Prohibition on Human Cloning. (b) Prohibitions on Human Cloning-It shall be unlawful
for any person or other legal entity, public or private-(l) to conduct or attempt to conduct human cloning; or
(2) to ship the product of nuclear transplantation in interstate or foreign commerce for the purpose of human
cloning in the United States or elsewhere. (c) Protection of Research-Nothing in this section shall be con-
strued to restrict practices not expressly prohibited in this section." Human Cloning Prohibition Act of 2002,
S. 2439, 107th Cong. (2001), LEXIS 2001 CONG US S 2439.
170. Section 4. Prohibition on Human Cloning. Definitions-In this section:
(1) Human Cloning - the term 'human cloning' means implanting or attempting to im-
plant the product of nuclear transplantation into a uterus or the functional equivalent of a
uterus. (b) Ethical Requirements for Nuclear Transplantation Research: (a) Definitions-
in this section: (2) nuclear transplantation- the term 'nuclear transplantation' means trans-
ferring the nucleus of a human somatic cell into an oocyte from which the nucleus or all
chromosomes have been or will be removed or rendered inert.
Id.
171. (d) Penalties- (1) criminal penalties-whoever intentionally violates paragraph (1) or (2)
of subsection (b) shall be fined under this title and imprisoned not more than 10 years. (2)
Civil Penalties-whoever intentionally violates paragraph (1) or (2) of subsection (b) shall
be subject to a civil penalty of $1,000,000 or three times the gross pecuniary gain resulting
from the violation, whichever is greater. (3) Forfeiture-any property, real or personal, de-
rived from or used to commit a violation or attempted violation of the provisions of sub-
section (b), or any property traceable to such property, shall be subject to forfeiture to the
United States in accordance with the procedures set forth in chapter 46 of title 18, United
States Code.
Id.
172. Id.
173. Human Cloning Prohibition Act 2001, H.R.2505, 107th Cong. (2001), LEXIS 2001 CONG US HR
2505.
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The Human Cloning Prohibition Act 2001 (H.R. 2505) amends Title
18 of the United States Code by establishing a comprehensive ban on human
cloning and prohibiting the importation of a cloned embryo, or any product
derived from such embryo.174 Any person or entity that is convicted of vio-
lating this prohibition is subject to a fine or imprisonment of not more than
10 years, or both.'75 In addition, H.R. 2505 provides a civil penalty of not
less than $1,000,000 for any person who receives a monetary gain from clon-
ing humans.'76 However, H.R. 2505 does not prohibit the use of cloning
technology to produce molecules, DNA, cells, tissues, organs, plants, or
animals. 77 In addition to federal legislation regarding human cloning, many
states have enacted laws dealing with cloning; seven states currently prohibit
cloning in some form.
78
At first glance, it may not seem that legislation regulating or prohib-
iting human cloning would be relevant to the development of stem cell re-
search legislation. However, H.R. 2505 is crucial to the subsequent direction
or development that legislation addressing stem cell research will take in the
following months. The current United States policy on stem cell research
limits federal funding to stem cell lines established prior to August 2001 and
permits research on excess embryos from in vitro fertilization. 7 9 However,
private entities can choose to be ineligible for federal funding and continue
to carry out research without these restrictions. By passing a bill, such as
H.R. 2505, that proposes a blanket prohibition on cloning without differenti-
ating between therapeutic and reproductive cloning, research entities that
forego federal funds because of the imposed restrictions will find their work
limited beyond the requirements for federal funding. The bill does not per-
mit the creation or importation of embryos or products from embryos created
174. Section 2 Prohibition on Human Cloning (a) In General:
Title 18, United States Code, is amended by inserting after Chapter 15, the following:
Chapter 16-Human Cloning Sec. 302. Prohibition on human cloning (a) In General-it
shall be unlawful for any person or entity, public or private, in or affecting state com-
merce, knowingly-(1) to perform or attempt to perform human cloning; (2) to participate
in an attempt to perform human cloning; or (93) to ship or receive for any purpose an em-
bryo produced by human cloning or any product derived from such embryo. (9b) Importa-
tion-it shall be unlawful for any person or entity, public or private, knowingly to import
for any purpose an embryo produced by human cloning, or any product derived from such
embryo.
Id.
175. "Section 2. Section 302(c). Penalties- (1) criminal penalty-any person or entity that violates this
section shall be fined under this title or imprisoned not more than 10 years, or both." Id.
176. "(2) Civil penalty-any person or entity that violates any provision of this section shall be subject to,
in the case of a violation that involves the derivation of a pecuniary gain, a civil penalty of not less than
$1,000,000.00 and not more than an amount equal to the amount of the gross gain multiplied by 2, if that
amount is greater than $1,000,000.00." Id.
177. "Section 302(d). Scientific Research-nothing in this section restricts areas of scientific research not
specifically by this section, including research in the use of nuclear transfer or other cloning techniques to
produce molecules, DNA, cells other than human embryos, tissues, organs, plants, or animals other than hu-
mans." Id.
178. State Human Cloning Laws, http://www.ncsl.org/programs/health/Genetics/rt-schl.htm, (May 9,
2002). (on file with author)
179. Mitch Frank, How Bush Got There, TtME MAGAZINE, Aug. 20, 2001, at 18.
2002]
Journal ofLegislation
by cloning for therapeutic purposes, regardless of the source of the funding
for such projects. The restrictions on stem cell research after August 2001
are not prohibitions on the research itself but rather on the parameters of
what federal funding. Here this bill prohibits research on cloning itself.
Since therapeutic cloning is an important and viable source of stem cells, a
blanket prohibition on all cloning will directly affect stem cell research.
This interplay of seemingly unconnected regulations may prove to have quite
an effect on the progress of scientific innovation regarding stem cells.
Some members of Congress claim that the only way to regulate clon-
ing is with an absolute ban on that research in the United States. 8° Those
opposed to a complete ban on cloning would prefer to see a ban that would
only "prohibit cloning when there was an intent to create a pregnancy and
would still allow scientists to clone human embryos for experimental pur-
poses."' 81 However, many feel that if any form of cloning, such as therapeu-
tic cloning, that offers a benefit that arguably outweighs the inherent ethical
difficulties, is permitted, then reproductive cloning will be virtually impossi-
ble to regulate. 8 2 The reasoning behind the complete cloning ban passed by
the House of Representatives comes from the concern about regulating clon-
ing and the early successes regarding the applicability of adult stem cells.'83
This research involving adult stem cells is promising but still considered to
be scientifically and technologically limited and should not be considered as
an alternative source to embryonic stem cell research. 84  Thus, such a clon-
ing bill prohibiting therapeutic cloning would eliminate an important re-
search tool in understanding stem cells and developing their therapeutic uses
and applications.
Despite the seemingly undirected and confusing legislative situation
currently in place in the United States, there are still many interesting and
valid ideas regarding the legislative direction stem cell research should take
in the near future. The United States system does not benefit from an over-
arching piece of legislation addressing a larger issue that affects both stem
180. H.R. REP. No. 107-170, at http://www.house.gov/judiciary/legreports.htm, (July 27, 2001). (on file
with author)
181. Id.
182. The concern here relates to what happens after the production of cloned embryos. Once embryos were
cloned and available in laboratories, there would be no effective way to control what was done with them.
Stockpiles of cloned human embryos "could be produced, bought and sold without anyone knowing it. Im-
plantation of cloned embryos, a relatively easy procedure, would take place out of sight." Id.
183. As stated in the Congressional Report addressing H.R. 2505, the House of Representatives found,
after hearing testimony on the issue, that "cloning human embryos for the sole purpose of destroying them for
their stem cells is unnecessary because of the successes that scientists have had with adult stem cells." Id.
Even though there has been promising research in involving the viability and applicability of adult stem cells,
studies are still inconclusive.
184. Studies in animals have illustrated that an approach to stem cell research primarily relying on adult
stem cells will be scientifically and technologically limited and in some cases the location of the adult stem
cells will prevent easy or safe access. However, since there are no real legal or ethical restrictions regarding
this research, important research should go forward in this area. But important biological differences do exist
between embryonic and adult stem cells and adult stem cell research should not be considered an alternative
source to embryonic stem cell research. National Bioethics Advisory Commission Ethical Issues in Human
Stem Cell Research, at http://bioethics.georgetown.edu/bac/stemcell.pdf (Sept. 1999).
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cell research and human cloning, such as HFE Act 1990, so the starting point
for regulation, and in the case of cloning, prohibition, is not as clear. The
various bills circulating in Congress do present different approaches and at
least begin the dialogue as to where to go next.
SECTION IV: THE INTERNATIONAL SITUATION
Various international and regional organizations have been attempt-
ing to tackle stem cell research and related sub fields. The United Nations
Educational, Scientific, and Cultural Organization (UNESCO), the Council
of Europe and the European Union have begun to address the status of the
embryo, stem cell research and human cloning by issuing various reports
from investigative committees and slowly developing pertinent treaties and
declarations. These international voices bring the debate into a global, rather
than purely national arena and further illustrate and clarify the challenges to
come regarding biotechnology and biomedical research and innovation. The
perspectives of these international organizations shed light on how an issue
as politically and ethically problematic and complex as stem cell research
and human cloning can be effectively addressed beyond the national arena.
The International Bioethics Committee, under the ambit of
UNESCO, published a report in April 2001 addressing the use of embryonic
stem cells in therapeutic research. 85 The report focused on the question of
whether it is "ethically acceptable to derive cells from a human embryo prior
to its implantation in utero in order to cultivate and investigate these cells in
the laboratory for therapeutic research.' 86 The report also recognized the
pluralistic nature of the opinions regarding embryo research and aimed at
highlighting "the various ethical arguments with a view to facilitating the
resolution at a national and international level, of a controversial matter.' ' 87
The overall focus of the United Nations with respect to human rights treaties
is to first provide a declaratory compass for member states to examine and
then enact treaties that embody the ideals set out in the original declaration.
This was the procedure the UN followed when developing the International
Covenant for Civil and Political Rights ("ICCPR") and the International
Covenant for Economic, Social, and Cultural Rights ("ICESCR"), both
which were based on the Universal Declaration of Human Rights. It would
not be surprising that this report from the International Bioethics Committee
could be the start of a larger effort regarding biomedical concerns. The dif-
ficulty with such a declaration and perhaps a treaty is likely to be the lack of
overall consensus regarding not only stem cell research but also ,cloning and
185. United Nations Educational, Scientific and Cultural Organization, International Bioethics Committee,
The Use of Embryonic Stem Cells in Therapeutic Research (Report of the IBC on the Ethical Aspects of
Human Embryonic Stem Cell Research), at http://www.unesco.org/ibc/en/reports/embryonic_ ibc-report.pdf
(Apr. 6, 2001).
186. Id. at § I.
187. Id.
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the status of the early embryo. Yet the UN does provide a much-needed in-
ternational forum for these issues, and their reports could be very useful and
instrumental in developments by regional organizations to address this area.
The International Bioethics Committee tackled a similar problem
when it created the Universal Declaration on the Human Genome and Hu-
man Rights. Since the creation of the International Bioethics Committee in
1993, the organization has worked for the development of an "international
instrument" for the protection of the human genome. 118 Once the Declaration
was finalized, UNESCO unanimously adopted the document in 1997 and the
General Assembly approved and endorsed it in 1998.189 This sort of declara-
tion on stem cell research or human cloning could be beneficial in directing
international development in these areas. The International Bioethics Com-
mittee, as well as UNESCO, has recognized the divergent viewpoints sur-
rounding stem cell research and thus realizes the difficulty of creating a
document that would adequately address all of these variant concerns. Even
though there are many resolutions from international organizations (most do
originate from the UN or satellite groups) that address relevant concerns,
such as the right to life and embryonic life, none of them directly addresses
stem cell research. Such a model treaty could provide suggestions as to po-
tentially appropriate provisions and language that other governments and
groups could emulate.
Generally, most regional and international human rights treaties,
such as the Universal Declaration of Human Rights of 1948,190 the Interna-
tional Covenant on Civil and Political Rights of 1966,'9' and The African
Charter on Human and People's Rights of 1981,192 specifically delineate a
right to life. The American Convention on Human Rights of 1969193 extends
this right to the conceived child.' 94 But none of these declarations or treaties
directly addresses the legal status of the embryo. Regional organizations,
such as the Council of Europe, are making strides towards developing a re-
gional treaty regime that does address different areas of biomedicine, such as
protection of the human embryo and fetus, 95 biomedical research, 196 and or-
gan transplantation. 1
97
188. The Universal Declaration on the Human Genome and on Human Rights, at
http://www.unesco.org/ibc/en/genome/index.htm (Nov. 11, 1997).
189. Id.
190. Universal Declaration of Human Rights, available at http://www.un.org/Overview/rights.html (Dec.
10, 1948).
191. International Covenant on Civil and Political Rights, available at http://www.tufts.edu/departments/
fietcher/multi/texts/BH498.txt (Dec. 16, 1966).
192. "Human beings are inviolable. Every human being shall be entitled to respect for his life and the
integrity of his person. No one may be arbitrarily deprived of this right." African (Banjul) Charter on Human
and People's Rights, at http://wwwl.umn.edu/humanrts/instree/zlafchar.htm (June 27, 1981). (on file with
author)
193. American Convention on Human Rights, at http://www.cidh.oas.org/Basicos/basic3.htm (Nov. 22,
1969).
194. "Every person has the right to have his life respected. This right shall be protected by law and, in
general, from the moment of conception. No one shall be arbitrarily deprived of his life." Id. at Art. 4(1).
195. Council of Europe, General Information Draft Protocol on the Protection of the Human Embryo and
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The Council of Europe's Convention for the Protection of Human
Rights and the Dignity of the Human Being Regarding the Application of
Biology and Medicine of 1997 (the Convention) 98 does not fully address
embryo research and leaves the responsibility of legislation to each country
with two conditions: 1) prohibition of producing human embryos for re-
search purposes; 9 9 2) adoption of rules designed to assure adequate protec-
tion for the embryo.200
In addition to these conditions, an additional Protocol to the Conven-
tion on the Prohibition of Cloning Human Beings21 garnered approval in
1998 and has currently been entered into force in eleven member states as of
January 3, 2001.202 Two other protocols to the Convention, the Draft Proto-
col on Biomedical Research (July 18, 2001)203 and the Draft Protocol on the
Protection of the Human Embryo and Fetus2", in addition to the Protocol
Fetus, at http://www.legal.coe.int/bioethics/gb/html/txt_p_info2.htm.
196. Council of Europe, Draft Additional Protocol to the Convention on Human Rights and Biomedicine
on Biomedical Research, at http://www.coe.int/T/E/LegalAffairs/Legal co-operation/Bioethics/ CDBI (July
18, 2001).
197. Council of Europe, Protocol No. 13 to the Convention for the Protection of Human Rights and
Fundamental Freedoms, concerning Transplantation of Organs and Tissues of Human Origin, at
http://conventions.coe.int/treaty/en/treaties/html/187.htm (Jan. 24, 2001).
198. Convention for the Protection of Human Rights and the Dignity of the Human Being Regarding the
Application of Biology and Medicine, at http://conventions.coe.int/Treaty/EN/CadreListeTraites. htm, (April
4. 1997).
199. "The creation of human embryos for research purposes is prohibited." Id. at Article 18(2).
200. "Where the law allows research on embryos in vitro, it shall ensure adequate protection of the em-
bryo." Id. at Article 18(1).
201. The Protocol expounds on certain articles in the Convention of Human Rights and Biomedicine. The
scope of the Protocol addresses the cloning of human beings. Additional Protocol to the Convention for the
Protection of Human Rights and Dignity of the Human Being With Regard to the Application of Biology and
Medicine, On the Prohibition of Cloning Human Beings, at http://conventions.coe.int/Treaty/EN/
CadreListetraites.htm (Jan. 12, 1998).
202. Cyprus, Czech Republic, Estonia, Georgia, Greece, Hungary, Portugal, Romania, Slovakia, Slovenia
and Spain. Id.
203. The main purpose of this draft Protocol is to:
build on the principles embodied in the Convention, with a view to protecting human
rights and dignity in the specific field of biomedical research" and to "define and safe-
guard fundamental rights in biomedical research." The Protocol is intended to cover the
complete range of biomedical research activities that involve interventions on human be-
ings; research on embryos and fetuses in vivo and pregnant women will be covered by
the Protocol. The Protocol will most likely address issues "such as the risks and benefits
of research . . . scientific quality, independent examination of research by an ethics
committee, information to be submitted to the ethics committee, information for research
participants, confidentiality and the right to information, dependent persons, undue in-
fluence, safety, duty of care and research in states not party to the Protocol.
General Information; Draft Protocol on Biomedical Research, at http://www.legal.coe.intfbioethics/
gb/html/txt_p_info.htm.
204. The working party responsible for the preparation of the Protocol is focusing on the ethical and legal
problems linked to "possible intervention on human embryos and fetuses." It is anticipated that the Protocol
will deal with the issue of consent as well as issues associated with professional standards, rules of conduct
applicable to intervention on embryos or fetuses as well as prohibition of trading in embryos and fetuses. The
draft Protocol will have several chapters, "including one on the protection of embryos in vitro, which will deal
with the safety and quality of the in vitro fertilization procedure." There is also a plan to create provisions on
the protection of embryos and fetuses in vivo and on embryonic and fetal cells and tissues. General Informa-
tion; Draft Protocol on the Protection of the Human Embryo and Fetus, at http://www.legal.coe.int/bioethics/
gb/html/txt_pinfo2.htm.
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addressing human cloning, begin to provide a fairly comprehensive legisla-
tive regime for biomedical research.
The Charter of Fundamental Rights of the European Union2 5 ex-
pressly prohibits reproductive cloning but does not directly address human
embryo research.0 6 The European Parliament, however, has stated its oppo-
sition to the creation of supernumerary embryos and therapeutic cloning,0 7
while the European Group on Ethics in Science and New Technologies to the
European Commission implemented Opinion 15, which calls for each coun-
try to forbid or permit embryonic research.20 8 The Group does consider the
creation of embryos with donated gametes as a source of stem cells as ethi-
cally unacceptable, 29 and it perceives the creation of embryos by cell nuclear
replacement as premature.210
Several other nations and international organizations have also en-
acted laws or issued policy statements regarding stem cell research and hu-
man cloning.211 In addition, the Denver Summit of Eight, the Council of
Europe, the World Health Organization, UNESCO's International Bioethics
Committee, the European Commission, and the Human Genome Organiza-
tion have called for a worldwide ban on the cloning of human beings.21 2
V. CONCLUSION
Stem cell research is a complex and challenging field. It is evolving
so rapidly that both international and national legislators are having diffi-
culty keeping up with its progress. The laws in place in the United Kingdom
provide a solid foundation that has proved to be adaptable when situations,
such as reproductive cloning, arise. The 1990Act is also a stable vantage
point from which new legislation can be developed and places the obtain-
ment of embryonic stem cells under the jurisdiction of one legislative um-
brella. There are still gaps, as the reproductive cloning situation illustrates.
The United States situation is still in its infancy and is developing from nu-
205. Charter of Fundamental Rights of the European Union, available at http://ue.eu.int/df/
docslen/CharteEN.pdf. (Dec. 7, 2000).
206. United Nations Educational, Scientific and Cultural Organization. International Bioethics Committee,
The Use of Embryonic Stem Cells in Therapeutic Research, Section 16, at
http://www.unesco.org/ibc/en/reports/embryonic ibc report.pdf (Apr. 17, 2001). (on file with author)
207. The European Parliament set forth this position in September 7, 2000 Resolution. Resolution on
Human Cloning, at http://www.europarl.eu.int/comparl/tempcom/genetics/links/b5_0710en.pdf (Sept. 7,
2000).
208. The Resolution, dated November 14, 2000, addresses the ethical aspects of stem cell research and use
and states that "stem cell research based on alternative sources (spare embryos, fetal tissues and adult stem
cells) requires a specific Community budget," available at http://europa.eu.int/conm/europeangroup_ ethics/
docs/avisl5_en.pdf. The Resolution also states that it is the responsibility of each member state to "forbid or
authorize embryo research." Id. at § 2.4.
209. Id.
210. Id.
211. Argentina, Australia, Belgium, Canada, China, Denmark, France, Germany, Israel, Japan, Norway,
Peru, Slovakia, South Korea, Spain, Sweden, Switzerland, and the United Kingdom already have laws or have
announced plans to pass laws prohibiting the cloning of human beings. H.R REP. No. 107-170, at
http://www.house.gov/judiciary/legreports.htm (July 27, 2001).
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merous directions. It is difficult to determine what direction the United
States legislative scheme will take at this point or under what agency regula-
tion of stem cell research will fall. The prohibition of cloning passed by the
House of Representatives jumpstarted the legislative process but could not
progress past the Senate.
Creating a treaty or a resolution on an international level may prove
to be more problematic then beneficial. Stem cell research, with its ties to
human cloning, garners very divergent responses worldwide. But it might be
possible for the International Bioethics Committee to draft a model resolu-
tion similar to the one addressing the human genome to at least aid countries
in developing legislation that adheres to an international standard but still
respects different ethical beliefs.
Stem cells and cloning are an exciting scientific and legal frontier
with much promise. The legislative developments in both the United States
and the United Kingdom illustrate different approaches to a common issue
and how such legislative developments will shape and ultimately determine
the direction of stem cell research, not only in the United States and the
United Kingdom, but worldwide.
212. Id.
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